5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended)
Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
1 - 43 . (canceled)
44 . A compound of Formula I
or a pharmaceutically acceptable salt thereof,
wherein:
W is N;
Y is C;
R 1 is absent;
R 2 is halogen or cycloalkyl;
R 3 is —OR 12 ;
R 4 is H;
R 5 is H;
R 6 and R 7 together form a 3- to 8-membered cycloalkyl ring, optionally substituted with R 15 , R 15′ , R 16 and/or R 16′ ;
R 8 is H;
R 9 is H;
R 10 is —CO 2 H;
R 11 is H;
R 12 is hydrogen, C 1-6 alkyl or substituted C 1-6 alkyl; and
R 15 , R 15′ , R 16 and/or R 16′ are independently C 1-6 alkyl.
45 . The compound according to claim 44 , or a pharmaceutically acceptable salt thereof, wherein R 2 is halogen.
46 . The compound according to claim 45 , or a pharmaceutically acceptable salt thereof, wherein R 2 is chloro.
47 . The compound according to claim 44 , or a pharmaceutically acceptable salt thereof, wherein R 2 is cycloalkyl.
48 . The compound according to claim 44 , or a pharmaceutically acceptable salt thereof, wherein R 6 and R 7 together form a 5-membered cycloalkyl ring, optionally substituted with R 15 , R 15′ , R 16 and/or R 16′ .
49 . The compound according to claim 44 , or a pharmaceutically acceptable salt thereof, wherein R 12 is substituted C 1-6 alkyl.
50 . The compound according to claim 49 , or a pharmaceutically acceptable salt thereof, wherein R 12 is
51 . The compound according to claim 44 selected from:
or a pharmaceutically acceptable salt thereof.
52 . The compound according to claim 44 selected from:
53 . A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 44 .
54 . A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 51 .
55 . A method of treating a hepatitis B virus infection in a human in need thereof, comprising administering to the human the compound or a pharmaceutically acceptable salt thereof according to claim 44 .
56 . A method according to claim 55 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
57 . A method according to claim 55 , wherein the compound is